期刊文献+

乳腺癌疫苗研究面临的机遇和挑战

Tumor vaccines for breast cancer:challenges and opportunities
暂未订购
导出
摘要 免疫治疗作为一种极具发展前景的治疗方式给乳腺癌的治疗带来了新的希望。近年来,关于乳腺癌疫苗的研究已陆续开展,将这些研究成果合理、快速地用于临床,为乳腺癌的免疫治疗提供了机遇与挑战。本文重点阐述乳腺癌治疗性疫苗的一些设计策略、临床应用情况,以及未来乳腺癌疫苗研究的发展和应用趋势。随着对肿瘤特异性免疫应答的深入了解、肿瘤特异性抗原的不断发现和鉴定,以及对肿瘤微环境的深入认识,乳腺癌疫苗的研发水平必将得到进一步提高,更好地服务于临床。 Immunotherapy as a promising therapy strategy is expected to bring new hope for breast cancer treatment. Recently several breast cancer vaccines have been developed. Rational and rapid application of these scientific discoveries in clinical therapies for breast cancer patients poses great challenges and opportunities. This article is aimed to elaborate on the design strategies, current clinical trials, and future progression and application of breast cancer therapeutic vac- cines. With the deepening of our understanding on the tumor-specific immune response and tumor microenvironment, and continuous discovery of new tumor-specific antigens, the research level of breast cancer vaccines will be further improved and will benefit the clinical treatment of breast cancer.
作者 任秀宝
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2010年第2期115-120,共6页 Chinese Journal of Cancer Biotherapy
基金 天津市科委重点项目资助(No.09jczdjc20400)~~
关键词 乳腺肿瘤 疫苗 免疫治疗 肿瘤抗原 免疫调节 breast neoplasms vaccine immunotherapy tumor antigen immune regulation
  • 相关文献

参考文献39

  • 1Esteva FJ.Monoclonal antibodies,small molecules,and vaccines in the treatment of breast cancer[J].Oncologist,2004,9(Suppl.3):4-9.
  • 2Acres B,Limacher JM,Bonnefoy J.Discovery and development of therapeutic cancer vaccines[J].Curr Opin Drug Discov Devel,2007,10(2):185-192.
  • 3Slamon DJ,Godolphin W,Jones LA,Holt JA,Wong SG,Keith DE,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science,1989,244(4905):707-712.
  • 4Chung MA,Luo Y,O′Donnell M,Rodriguez C,Heber W,Sharma S,et al.Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine[J].Cancer Res,2003,63(6):1280-1287.
  • 5Hodge JW.Carcinoembryonic antigen as a target for cancer vaccines[J].Cancer Immunol Immunother,1996,43(3):127-134.
  • 6Bednarek AK,Sahin A,Brenner AJ,Johnston DA,Aldaz CM.Analysis of telomerase activity levels in breast cancer:positive detection at the in situ breast carcinoma stage[J].Clin Cancer Res,1997,3(1):11-16.
  • 7Runnebaum IB,Nagarajan M,Bowman M,Soto D,Sukumar S.Mutations in p53 as potential molecular markers for human breast cancer[J].Proc Natl Acad Sci U S A,1991,88(23):10657-10661.
  • 8Tsuruma T,Iwayama Y,Ohmura T,Katsuramaki T,Hata F,Furuhata T,et al.Clinical and immunological evaluation of anti-apoptosis protein,survivin-derived peptide vaccine in phase Ⅰ clinical study for patients with advanced or recurrent breast cancer[J].J Transl Med,2008,6:24.
  • 9Sahin U,Türeci O,Chen YT,Seitz G,Villena-Heinsen C,Old LJ,et al.Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma:basis for polyvalent CT vaccine strategies[J].Int J Cancer,1998,78(3):387-389.
  • 10Baxevanis CN,Sotiropoulou PA,Sotiriadou NN,Papamichail M.Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy[J].Cancer Immunol Immuno-ther,2004,53(3):166-175.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部